SecBot SecBot
SECBOTREPLAY Home › Report › CTMX

CTMX · CytomX Therapeutics filed an 8-K reporting the results of its June 17,…

CytomX Therapeutics, Inc. · 8-K filed Jun 22, 2026 at 16:52 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Jun 22, 2026 at 16:52 ET

CytomX Therapeutics filed an 8-K reporting the results of its June 17, 2026 Annual Meeting. Stockholders approved a charter amendment to double authorized common shares from 300M to 600M, an amendment to the 2015 Equity Incentive Plan adding 6.5M new shares, and an amendment to the Employee Stock Purchase Plan adding 1M shares. These are routine governance and equity plan replenishments that enable future compensation grants and capital flexibility but signal no immediate operational change.

  • Stockholders approved an amendment to the certificate of incorporation increasing authorized common shares from 300,000,000 to 600,000,000.
  • Stockholders approved an amendment to the 2015 Equity Incentive Plan, increasing shares authorized for issuance by 6,500,000 shares.
  • Stockholders approved an amendment to the Employee Stock Purchase Plan, increasing shares authorized for issuance by 1,000,000 shares.
  • All seven proposals at the Annual Meeting were approved by stockholders; there were no contested matters or director departures.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access